@article{c929ab3f17774b30a7426873483c8c37,
title = "Psychotherapy claims surrounding pharmacotherapy initiation in children and adolescents with anxiety disorders",
abstract = "Objectives: Psychotherapy is an effective, recommended treatment for pediatric anxiety disorders. Nevertheless, individuals with mental health conditions often do not receive psychotherapy, with variation across provider types. This study sought to examine psychotherapy claims surrounding medication initiation in U.S. children with diagnosed anxiety disorders. Methods: The study cohort included privately insured children (3-17 years) with a diagnosed anxiety disorder initiating a medication to treat anxiety from 2004 to 2014. We examined psychotherapy claims in the 3 months before and 3 months after medication initiation and described children with multiple (2+) psychotherapy claims per 3-month period. Results: Of the 75,024 children initiating a medication for anxiety (median age = 14 years, 58% female), 35% had multiple psychotherapy claims before medication initiation, with variation by age, anxiety disorder, and psychiatric comorbidity and with little change across time. Psychotherapy claims after medication initiation varied by whether the child had prior psychotherapy: 80% in children with prior psychotherapy and 30% in children without prior psychotherapy claims (44% of children diagnosed by a psychiatrist, 21% of children diagnosed by a pediatrician). Conclusion: Many privately insured children do not have claims for psychotherapy before or after pharmacotherapy initiation for anxiety. Findings can inform future research and efforts to ultimately increase appropriate psychotherapy utilization in children with anxiety disorders.",
keywords = "adolescent, anxiety disorder, child, pharmacotherapy, psychotherapy",
author = "Bushnell, {Greta A.} and Dusetzina, {Stacie B.} and Compton, {Scott N.} and Gaynes, {Bradley N.} and Brookhart, {M. Alan} and Til St{\"u}rmer",
note = "Funding Information: 1Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina. 2Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee. 3Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina. 4Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina. *Current affiliation: Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York. Funding: Research reported in this publication was supported by the National Institute of Mental Health (Bethesda, MD) under Award Number F31MH107085 (G.A.B.) and, in part, under T32MH013043. The database infrastructure was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health, the Cecil G. Sheps Center for Health Services Research, UNC, the Comparative Effectiveness Research (CER) Strategic Initiative of UNC{\textquoteright}s Clinical Translational Science Award (UL1TR002489), and the UNC School of Medicine. Funding Information: Authors Dr. Bradley Gaynes and Dr. Stacie Dusetzina report no financial interests or potential conflicts of interest. Dr. Bushnell received support from the National Institute of Mental Health as a Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellow (F31MH107085) and currently under award number T32MH013043. Dr. Bushnell previously held a graduate research assistantship with GlaxoSmithKline and was the Merck fellow for the Center for Pharmacoepidemiology (both ended December 2015). Dr. Brookhart receives investigator-initiated research funding from the National Institutes of Health (NIH) and through contracts with the Agency for Healthcare Research and Quality{\textquoteright}s DEcIDE program and the Patient-Centered Outcomes Research Institute. Within the past 3 years, he has received research support from Amgen and AstraZeneca and has served as a scientific advisor for Amgen, Merck, and Glax-oSmithKline (honoraria/payment received by the institution). He has received consulting fees from RxAnte, Inc. and World Health Information Consultants. Dr. St{\"u}rmer receives investigator-initiated research funding and support as Principal Investigator (R01 AG056479) from the National Institute on Aging (NIA), and as Coinvestigator (R01 CA174453; R01 HL118255, R21-HD080214), NIH. He also receives salary support as Director of Comparative Effectiveness Research (CER), NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR002489), the Center for Pharmacoepidemiology (current members: Glax-oSmithKline, UCB BioSciences, Merck, Shire), and from pharmaceutical companies (Amgen, AstraZeneca, Novo Nordisk) to the Department of Epidemiology, University of North Carolina at Chapel Hill. Dr. St{\"u}rmer does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, BASF, AstraZeneca, and Novo Nordisk. Dr. Compton receives research support from the National Institute of Mental Health, NC GlaxoSmithKline Foundation, Mursion, Inc. and has been a consultant for Shire, received honoraria from the Journal of Consulting and Clinical Psychology, Nordic Long-Term OCD Treatment Study Research Group, and The Center for Child and Adolescent Mental Health, Eastern and Southern Norway, and given expert testimony for Duke University. Publisher Copyright: {\textcopyright} Mary Ann Liebert, Inc., publishers 2019.",
year = "2019",
month = mar,
doi = "10.1089/cap.2018.0108",
language = "English (US)",
volume = "29",
pages = "100--106",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "2",
}